Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Antifungal prophylaxis in liver transplant recipients Eschenauer GA; Lam SW; Carver PLLiver Transpl 2009[Aug]; 15 (8): 842-58Although the overall incidence of fungal infections in liver transplant recipients has declined, these infections still contribute significantly to the morbidity and mortality of patients with risk factors for infection. Although antifungal prophylaxis has been widely studied and practiced, no consensus exists on which patients should receive prophylaxis, with which agent, and for what duration. Numerous studies have attempted to ascertain independent risk factors for invasive fungal infections in liver transplant patients, and these data, in addition to clinical trials, identify several patient groups at exceedingly high risk of fungal infection. These include retransplant patients, patients with renal failure requiring hemodialysis or renal replacement therapy, and those requiring reoperations after transplant. Because the majority of infections occur in the first month after transplantation, prophylaxis should be continued for 4-6 weeks. However, local epidemiology and research should guide decisions regarding choice of agent as well as overall development of interinstitutional guidelines, because the incidence and spectrum of infection may differ dramatically among institutions. Liver Transpl 15:842-858, 2009. (c) 2009 AASLD.|Antifungal Agents/*therapeutic use[MESH]|Aspergillosis/etiology[MESH]|Aspergillus/metabolism[MESH]|Clinical Trials as Topic[MESH]|Cytomegalovirus Infections/etiology[MESH]|Cytomegalovirus/metabolism[MESH]|Environmental Exposure[MESH]|Female[MESH]|Humans[MESH]|Liver Transplantation/*adverse effects/*methods[MESH]|Male[MESH]|Mycoses/*complications[MESH]|Postoperative Complications[MESH]|Risk Factors[MESH]|Treatment Outcome[MESH] |